Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy

被引：3

作者：

Furuya Y. ^{[1
]}

Ohta S. ^{[1
]}

Sato N. ^{[1
]}

Kotake T. ^{[1
]}

Masai M. ^{[1
]}

机构：

[1] Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Ichihara

来源：

International Urology and Nephrology | 2002年 / 33卷 / 1期

关键词：

Public Health; Japan; Prostate Cancer; Clinicopathological Feature; Radical Prostatectomy;

D O I：

10.1023/A:1014461105701

中图分类号：

学科分类号：

摘要：

In order to examine the characteristics of patients with nonpalpable prostate cancer (T1c cancer) in Japan, patients treated with radical prostatectomy were compared with those with palpable (T2) cancer. Prostate-specific antigen (PSA) level in patients with T2b disease was significantly higher than those with T1c and T2a tumors. At the time of radical prostatectomy, 78%, 71% and 31% of patients with T1c, T2a, and T2b, respectively, had organ-confined disease. When insignificant cancer was defined as volume 0.5 ml or less and Gleason score less than 5, only 2 of 34 (5.9%) with clinical T1c disease were clinically insignificant. T1c cancers were clinically significant and clinicopathological features of T1c tumors were similar to T2a tumors. PSA measurement could detect potentially curable prostate cancer.

引用

页码：73 / 76

页数：3

共 16 条

[1]

Oesterling J.E., Suman V.J., Zincke H., Bostwick D.G., PSA-detected (clinical stage T1c or B0) prostate cancer, Urol Clin N Am, 20, (1993)

[2]

Lerner S.E., Seay T.M., Blute M.L., Bergstralh E.J., Barrett D., Zincke H., Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis, J Urol, 155, (1996)

[3]

Elgamal A.A., Van Poppel H.P., Van De Voorde W.M., Van Dorpe J.A., Oyen R.H., Baert L.V., Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view, J Urol, 157, (1997)

[4]

Carter H.B., Sauvageot J., Walsh P.C., Epstein J.I., Prospective evaluation of men with stage T1c adenocarcinoma of the prostate, J Urol, 157, (1997)

[5]

Ghavamian R., Blute M.L., Bergstralh E.J., Slezak J., Zincke H., Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy, Urology, 54, (1999)

[6]

Oesterling J.E., Kumamoto Y., Tsukamoto T., Girman C.J., Masumori N., Jacobsen S.J., Lieber M.M., Serum prostate-specific antigen in a community-based population of healthy Japanese men: Lower values than for similarity aged white men, Brit J Urol, 75, (1995)

[7]

Yatani R., Shiraishi T., Nakakuki K., Kusano I., Takanari H., Hayashi T., Stemmermann G.N., Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 and 1982-1986, J Natl Cancer Inst, 80, (1988)

[8]

Yasuhara K., Prostate-specific antigen density and velocity for detection of localized prostate cancer, Chiba Med J, 72, (1996)

[9]

Gleason D.F., Mellinger G.T., Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging, J Urol, 111, (1974)

[10]

Sobin L.H., Wittekind C.H., UICC TNM Classification of Malignant Tumours, 5th edn., pp. 170-173, (1997)

← 1 2 →